
Explore the pharmaceutical value chain from discovery through phase three trials, regulatory approval, manufacturing, and market access, and examine the four industry players and the pricing dilemma.
Explore why pharma shifted from blockbusters to niche busters, driven by the patent cliff, Orphan Drug Act incentives, and high R&D costs.
Marketing, sales, and commercial operations form an integrated engine that moves a new therapy from lab to patient by aligning strategy, execution, and data-driven insights.
Unpack unmet medical need, market size, and risk-adjusted net present value (NPV) to explain why only a few drug ideas survive pre-clinical work and become billion-dollar blockbusters.
Define how a blockbuster drug emerges from a strategic blueprint called the target product profile, selecting primary, secondary, surrogate, and comparative endpoints to satisfy the FDA, payers, and physicians.
Explore how regulatory strategy and intellectual property shape pharma profits, from FDA review timelines and priority pathways to the core patent and patent thicket guarding a drug's time-to-market window.
Explore how big pharma uses strategic acquisitions and licensing to outpace the patent cliff, balancing due diligence, risk-adjusted valuation, and AI-driven discovery for global expansion.
Explore how biopharma valuation gaps between startups and investors shape mergers and acquisitions and strategic partnerships, showing why alliances often outpace takeovers.
Apply the stp framework to map healthcare segments and target audiences, then craft positioning through storytelling. Align teams for a unified message to doctors, payers, patients, and pharmacists.
The marketing mix in pharma turns a lab breakthrough into patient access by aligning product, place, and promotion through a unified strategy, ensuring benefits justify risks and compliant storytelling.
Explore how pharma embraces omnichannel marketing with connected, compliant, data-driven strategies that balance promotional and non-promotional content, ensure MLR approvals, and measure ROI.
Explore why the list price versus net price creates the rebate bubble, driven by PBMs, rebates, and discounts, and how three fixes and value-based contracts could transform pricing.
Plan an 18-month pre-launch countdown to build a billion-dollar commercial army, sizing, structuring, and mapping territories with top-down and bottom-up methods, including cams and MSLs for formulary access.
Explore how to size and deploy pharma sales forces, from infantry vs special ops models to workload math, key account management, and omnichannel integration.
Monitor KPIs and TRX from launch to gauge adoption, market share, and access. Drive lifecycle management to extend value through new indications and improved formulations for long-term competitive advantage.
Explore how copay accumulators and manufacturer assistance shape patient access and adherence to expensive specialty drugs, the rise of patient support hubs, and the push to redesign the pharma ecosystem.
Forecast the drug's performance using a waterfall model, convert volume to net sales, and build a data-driven business case to secure funding with a compelling NPV justification.
Navigate the pharma compliance landscape, balancing commercial goals with patient protection through accuracy, transparency, integrity, and accountability. Learn about anti-kickback statute and Sunshine Act, fair balance, and MLR review.
AI-powered commercialization reshapes pharma from mass blockbuster to hyper personalized therapies. AI copilots guide sales and marketing with doctor data, patient outcomes, and value-based contracts.
Drive the future of medicine with real world evidence from health records, claims, and wearables, using AI to enable smarter trials, synthetic controls, and proven payer value.
*This course contains the use of artificial intelligence*
This comprehensive course provides the essential knowledge and strategic frameworks for individuals aspiring to, or currently working in, the dynamic commercial side of the pharmaceutical and biotech industries. If you want to understand how a promising molecule transforms into a market-leading product, this is the course for you.
We focus on the non-stop journey from late-stage development through to successful market entry and long-term brand management, specifically excluding the complex area of Market Access.
What You Will Master:
Commercial Foundations: You'll begin by mastering the pharmaceutical value chain, understanding key business models, and identifying the critical roles played by Marketing, Sales, and Commercial Operations. Learn how to look at a pipeline asset with a strategic commercial lens.
Brand Strategy & Positioning: Learn the core marketing skills required to succeed in pharma. This includes conducting market sizing, developing a compelling Target Product Profile (TPP), and creating an irresistible Brand Story that resonates with physicians, patients, and pharmacists. We dive deep into the strategic process of Segmentation, Targeting, and Positioning (STP).
Sales and Launch Excellence: The course provides a rigorous, step-by-step guide to developing and executing a successful drug launch. You will learn the critical milestones of a 12-18 month pre-launch plan, how to determine optimal sales force sizing, deployment strategy, and the critical importance of Key Account Management (KAM).
The Regulatory Imperative: Success in pharma is predicated on compliance. A dedicated module teaches you the importance of Intellectual Property (IP), ethical promotion, and strictly adhering to regulations like anti-kickback statutes and transparency laws, ensuring your commercial actions are always compliant.
Future-Proofing Your Career: Finally, we cover critical business skills, including developing robust revenue forecasts and building data-driven business cases for investment. We conclude with a look at how technologies like AI are shaping the future of sales and marketing in healthcare.
By the end of this course, you will possess a strategic, integrated view of pharmaceutical commercialization that is highly valued by global biopharma employers.